Table 2.

Logistic regression analysis of significant polymorphisms in different groups.

SNP ID	Gene	base change	Group 1a			Group 2b			OR (95% CI)	P value	Clinical outcomes	subgroup
			WT	HE	HO	WT	HE	HO
rs4150558	GTF2H1	T > A	22	6	1	794	96	2	2.74(1.23–6.09)	0.013	anemia	none
rs10857	POLD3	A > C	65	46	4	342	370	107	0.55(0.39–0.76)	3.01 × 10−4	neutropenia	none
rs6592576	POLD3	G > A	65	46	4	346	366	108	0.56(0.41–0.77)	3.58 × 10−4	neutropenia	none
rs12727	RPA1	C > G	23	7	4	688	205	18	1.81(1.02–3.21)	0.044	thrombocytopenia	none
rs3219281	POLD1	G > A	21	10	3	679	222	15	1.87(1.4–3.34)	0.035	thrombocytopenia	none
rs3219341	POLD1	G > A	21	10	3	679	220	17	1.84(1.03–3.26)	0.039	thrombocytopenia	none
rs1726801	POLD1	G > A	21	10	3	676	213	17	1.86(1.05–3.30)	0.033	thrombocytopenia	none
rs3176721	XPA	C > A	92	39	4	385	86	6	1.88(1.28–2.76)	0.001	clinical benefit	AC
rs3218804	GTF2H4	G > A	102	32	1	415	62	0	2.29(1.43–3.66)	0.001	clinical benefit	AC
rs4150558	GTF2H1	T > A	0	3	0	183	18	1	23.45(2.64–208.13)	0.005	anemia	SCC
rs2290280	CCNH	C > A	1	0	2	160	37	8	28.53(1.69–481.13)	0.020	anemia	SCC
rs8067195	RPA1	A > G	1	0	2	150	46	9	6.93(1.44–33.49)	0.016	anemia	SCC
rs6416887	RPA1	A > G	1	0	2	142	52	10	6.55(1.32–32.44)	0.021	anemia	SCC
rs4150339	ERCC5	A > G	9	4	1	165	34	0	3.93(1.15–13.41)	0.029	gastrointestinal toxicity	SCC
rs3786136	RPA1	G > A	2	2	1	154	49	1	4.71(1.10–20.12)	0.037	thrombocytopenia	SCC
rs4150339	ERCC5	A > G	13	2	2	242	44	2	3.06(1.15–8.19)	0.026	gastrointestinal toxicity	TP
rs4253002	ERCC6	G > A	12	5	0	274	13	1	7.81(2.27–26.88)	0.001	gastrointestinal toxicity	TP
rs1726801	POLD1	G > A	18	11	4	192	66	2	3.03(1.59–5.77)	0.001	neutropenia	TP
rs1673041	POLD1	A > C	7	16	10	134	107	20	3.46(1.97–6.09)	1.70 × 10−5	neutropenia	TP
rs3219341	POLD1	G > A	18	11	4	193	66	2	3.03(1.59–5.75)	0.001	neutropenia	TP
rs1799793	ERCC2	G > A	2	5	0	196	26	3	7.91(2.02–30.96)	0.003	anemia	GP
rs20580	LIG1	A > C	2	15	4	110	85	19	3.21(1.53–6.74)	0.002	gastrointestinal toxicity	GP
rs4253212	ERCC6	G > A	9	3	2	175	41	1	3.31(1.26–8.72)	0.015	neutropenia	GP
rs4150558	GTF2H1	T > A	9	3	1	239	33	0	4.39(1.37–14.08)	0.013	anemia	NP
rs326222	DDB2	A > G	23	22	9	251	165	15	2.07(1.32–3.23)	0.001	neutropenia	age ≤ 58
rs12150513	RPA1	A > C	31	14	7	263	150	12	2.18(1.32–3.61)	0.002	neutropenia	age ≤ 58
rs4150339	ERCC5	A > G	34	5	3	366	61	0	2.53(1.23–5.22)	0.012	gastrointestinal toxicity	age>58
rs2296147	ERCC5	A > G	24	12	6	272	146	8	2.10(1.21–3.64)	0.008	gastrointestinal toxicity	age>58
rs4150360	ERCC5	G > A	23	13	6	266	152	9	3.07(1.70–5.55)	2.12 × 10−4	gastrointestinal toxicity	age>58
rs4771436	ERCC5	A > C	31	7	3	190	202	33	0.37(0.19–0.72)	0.003	gastrointestinal toxicity	age>58

AC, Adenocarcinoma; SCC, Squamous Cell Carcinoma; TP, Paclitaxel combined with cisplatin regimen; GP, Gemcitabine combined with cisplatin regimen; NP, navelbine combined with cisplatin regimen; OR, Odd ratio; CI, Confidence interval; WT, wild type; HE, heterozygote; HO, mutant homozygote.

^aGroup 1 means severe toxicity in toxicity analysis, bad response in clinical benefit or response rate analysis.

^bGroup 2 means light toxicity in toxicity analysis, good response in clinical benefit or response rate analysis.